Theravance Inc. (THRX) announced after the bell Thursday that it received a letter from the FDA indicating that Theravance's response to the November 2009 Complete Response letter for the telavancin New Drug Application for is incomplete and that the review clock will not start until the FDA receives a complete response. The stock is now trading lower by 1.49 on 18K shares.
Theravance Inc. fell in early trade Thursday, but settled into a narrow range for the majority of the session. The stock finished down by 0.35 at $13.50.
For comments and feedback: editorial@rttnews.com